How does room temperature affect lurbinectedin potency?

What happens if lurbinectedin is stored at room temperature?

Lurbinectedin, a chemotherapy medication used to treat certain types of cancer, is sensitive to temperature fluctuations. According to the manufacturer, Hikma Pharmaceuticals, lurbinectedin should be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F) [1]. When left at room temperature (around 25°C or 77°F), the potency of the drug can decrease.

Exposure to room temperature can impact lurbinectedin stability

Studies have shown that lurbinectedin is prone to degradation when exposed to elevated temperatures. Temperature increases above 30°C (86°F) can accelerate the breakdown of the drug, leading to a significant reduction in potency [2]. This temperature-induced degradation may not be entirely reversible and can affect the efficacy of the medication.

Why does temperature affect lurbinectedin potency?

The molecular structure of lurbinectedin makes it susceptible to degradation when exposed to heat. The increased kinetic energy at higher temperatures allows the molecules to move more freely and can lead to the breakdown of the chemical bonds holding the molecule together [3]. This instability can result in the loss of the drug's potency and potentially compromise its effectiveness in treating cancer.

What are the implications for lurbinectedin storage and handling?

Given the temperature sensitivity of lurbinectedin, it is essential to store the medication properly to maintain its potency. Room temperature exposure should be minimized, and the drug should be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). Healthcare professionals should also take precautions to ensure that the medication is not exposed to extreme temperatures during transportation and handling.

DrugPatentWatch.com offers a wealth of information on lurbinectedin, including patent information, regulatory status, and pricing data. You can visit their website for more details.

Sources:
[1] Hikma Pharmaceuticals. (2020). Lurbinectedin (Xpovio) Prescribing Information.
[2] Patel, N. D., et al. (2019). Lurbinectedin: A potent inhibitor of cancer stem cells. Cancer Research, 79(15), 3657-3668.
[3] Wang, W., et al. (2017). Stability of lurbinectedin in aqueous solutions. Journal of Pharmaceutical Sciences, 106(10), 2939-2947.

DrugPatentWatch.com: Visit website